100
Participants
Start Date
March 31, 2025
Primary Completion Date
April 30, 2028
Study Completion Date
September 30, 2028
MCLA-129
MCLA-129 will be administered by intravenous infusion on the 28-day treatment cycle.
The First Affiliated Hospital of Anhui Medical University, Hefei
The First Hospital of Lanzhou University, Lanzhou
Dongguan People's Hospital, Dongguan
Foshan First People's Hospital, Foshan
Guangdong General Hospital, Guangzhou
Hebei University Affiliated Hospital, Baoding
Harbin Medical University Affiliated Cancer Hospital, Harbin
Henan Cancer Hospital, Zhengzhou
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Hunan Cancer Hospital, Changsha
Nantong Cancer Hospital, Nantong
Jilin Cancer Hospital, Changchun
The First Hospital of Jilin University, Changchun
The First Affiliated Hospital of China Medical University, Shenyang
Shandong Cancer Hospital, Jinan
The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an
Tianjin Cancer Hospital, Tianjin
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
Beijing Chest Hospital, Beijing
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
INDUSTRY